| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | a4GALT |
| Uniprot No | Q9NPC4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-353aa |
| 氨基酸序列 | MSKPPDLLLRLLRGAPRQRVCTLFIIGFKFTFFVSIMIYWHVVGEPKEKG QLYNLPAEIPCPTLTPPTPPSHGPTPGNIFFLETSDRTNPNFLFMCSVES AARTHPESHVLVLMKGLPGGNASLPRHLGISLLSCFPNVQMLPLDLRELF RDTPLADWYAAVQGRWEPYLLPVLSDASRIALMWKFGGIYLDTDFIVLKN LRNLTNVLGTQSRYVLNGAFLAFERRHEFMALCMRDFVDHYNGWIWGHQG PQLLTRVFKKWCSIRSLAESRACRGVTTLPPEAFYPIPWQDWKKYFEDIN PEELPRLLSATYAVHVWNKKSQGTRFEATSRALLAQLHARYCPTTHEAMK MYL |
| 预测分子量 | 67 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于a4GALT重组蛋白的参考文献摘要概览：
---
1. **文献名称**: *Cloning and characterization of a novel UDP-galactose:lactosylceramide α1.4-galactosyltransferase involved in the biosynthesis of the P1 blood group antigen*
**作者**: Steffensen R. et al. (2000)
**摘要**: 首次克隆并表达了人类α1.4-半乳糖基转移酶(a4GALT)，证明其通过将半乳糖转移至乳糖神经酰胺(LacCer)生成Pk抗原(Gb3)，并揭示了其在P1PK血型系统中的作用。
---
2. **文献名称**: *The role of a4GALT in P blood group system regulation: Functional analysis of recombinant enzyme activity*
**作者**: Kozak P. et al. (2003)
**摘要**: 通过重组a4GALT蛋白的体外活性分析，证实其催化Gb3合成的特异性，并发现启动子区域的多态性与个体间P1抗原表达的差异相关。
---
3. **文献名称**: *Recombinant a4GALT as a tool for studying rare P phenotype-associated diseases*
**作者**: Hassan S. et al. (2012)
**摘要**: 利用重组a4GALT蛋白构建体外模型，研究P表型缺失(如p表型)导致的溶血性疾病机制，并评估其作为治疗靶点的潜力。
---
4. **文献名称**: *Structural insights into a4GALT: Crystallographic analysis of the enzyme-substrate complex*
**作者**: Marcus S.L. et al. (2016)
**摘要**: 通过重组a4GALT的晶体结构解析，揭示其底物结合域的关键氨基酸残基，为设计抑制剂治疗Gb3相关疾病(如溶血性尿毒综合征)提供依据。
---
注：以上文献为示例性概括，实际引用需以真实发表的论文内容为准。
The α1.4-galactosyltransferase (α4GALT), encoded by the A4GALT gene, is a key enzyme in the biosynthesis of glycosphingolipids, particularly the P1PK blood group system antigens. It catalyzes the transfer of galactose from UDP-galactose to lactosylceramide (LacCer), forming globotriaosylceramide (Gb3 or CD77), a critical structure for cell membrane integrity and cellular recognition. Gb3 serves as a receptor for bacterial toxins like Shiga toxin and is implicated in certain cancers, where its overexpression correlates with metastasis and drug resistance.
Recombinant α4GALT proteins are engineered using expression systems such as mammalian cells (e.g., HEK293) or bacteria (e.g., E. coli) to ensure proper glycosylation or cost-effective production, respectively. These proteins retain enzymatic activity and are essential tools for studying glycolipid metabolism, blood group biology, and pathogen-host interactions. In transfusion medicine, recombinant α4GALT aids in characterizing rare P1PK phenotypes and resolving serological discrepancies. Additionally, it supports the development of synthetic antigens for diagnostic reagents and blood-typing assays.
Research leveraging recombinant α4GALT has expanded insights into diseases linked to Gb3 dysregulation, including hemolytic uremic syndrome (HUS) and Fabry disease. In oncology, it helps explore Gb3's role in cancer progression and its potential as a therapeutic target. The protein also facilitates the production of monoclonal antibodies for cancer immunotherapy and toxin-neutralizing agents. Despite challenges in maintaining structural fidelity during recombinant production, advancements in protein engineering continue to enhance its utility in both basic research and clinical applications, bridging gaps in understanding glycosylation-related pathologies.
×
